Kauvery hospitals rope in Ms Dhoni as brand ambassador
Kauvery group of hospitals, a leading healthcare chain in Tamil Nadu, has roped in former Indian cricket captain Mahendra Singh Dhoni as its brand ambassador
Kauvery group of hospitals, a leading healthcare chain in Tamil Nadu, has roped in former Indian cricket captain Mahendra Singh Dhoni as its brand ambassador
The Endosonography allows the use of EUS guided Fine needle aspiration for accurate diagnosis of GI cancers without the need for conventional biopsies
The company plans to invest in technology, business development, product innovation, and development across India
The preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone jointly developed by CureVac and GSK compared to CureVac’s first-generation mRNA backbone
FDA approval of the first interchangeable biosimilar insulin will drive the US Insulin biosimilar market, says Kuick Research.
The company's discovery services support a wide range of global innovator companies from start-ups to large pharma companies, across a diverse set of therapeutic areas including oncology, CNS, antivirals, and inflammation among others
It measures 9 French (3 millimetres) in diameter upon insertion and removal from the body. While in the heart, it expands to support the heart’s pumping function, providing flow greater than 3.5 L/min
Thermo Fisher’s kits leverage an updated design from the original TaqPath assays, targeting eight different genes across three regions of the virus that causes Covid-19
The group, known as the HIV Obstruction by Programmed Epigenetics (HOPE) Collaboratory, will be led by researchers at Gladstone Institutes, Scripps Research Florida, and Weill Cornell Medicine. Their approach, which aims to both silence and permanently remove HIV from the body, takes advantage of knowledge about how other viruses have become naturally inactivated over time.
Price erosion, weak demand for acute portfolio and low ANDA approvals in the US weighed on the performance of Indian pharma in Q1FY22. However, the scenario is expected to change in H2FY22 when new approvals and inspections resume
Subscribe To Our Newsletter & Stay Updated